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Abstract 
Neuromyelitis optica (NMO) is an inflammatory demyelinating autoimmune disease with severe, 
tremendously incapacitating, consequences in the patient’s health and wellbeing. Until 2004, NMO was 
considered a restricted type of Multiple Sclerosis but in the same year an auto-antibody reacting against 
aquaporin-4 (NMO-IgG) was found to be related with NMO and it was considered the main etiologic 
agent of this disease. Its detection is very sensitive and specific allowing an early diagnosis and a better 
treatment and prognosis. With this tool, a spectrum of diseases including other autoimmune diseases was 
found to have NMO-IgG antibodies and a new classification named Neuromyelitis Optica Spectrum 
Disorders (NMOSD) was created. In this review, we sum up the developments in this field associated 
with other autoimmune diseases. We approach the latest discoveries in the diagnosis like the new 
biomarkers that will possibly be used in the close future or the developments in the neuroimaging 
techniques. We reviewed the literature and synthesized case reports of NMO patients with concurrent 
autoimmune diseases and the information from useful larger studies. Finally, we summarize the 
commonly used treatments in NMO and we try to specify the best treatment for NMO with simultaneous 
autoimmune disease. This review updates the information about this issue and raises the awareness of 
rheumatologists for these severe diseases. 
Keywords: NMOSD; Autoimmune; NMO-IgG; Biomarkers; Treatment.  
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Introduction 
Neuromyelitis Optica (NMO) is an inflammatory demyelinating disease of the central nervous system. 
NMO is a severe, idiopathic and immune-mediated disease that causes lesions predominantly in the optic 
nerves and spinal cord but usually spares the brain, unlike Multiple Sclerosis (MS) [1]. 
Until 2004, the diagnosis of NMO was made based on major and minor clinical and paraclinical criteria 
with special attention to the presence of pleocytosis (more than 50 leukocytes/mm3) on cerebrospinal 
fluid (CSF) and the lack of complete recovery after the attack. Because of the clinical similarity between 
MS and NMO patients were sometimes treated for MS for a long time until NMO diagnosis could be 
made [2].  
In 2004, Lennon and colleagues identified for the first time in NMO or high-risk NMO patients the 
presence of serum IgG antibodies against glia limitans, brain vessel walls, Virkow-Robin spaces and 
ependyma, and named it NMO-IgG. This autoantibody showed high specificity (90.9%) for NMO and 
high-risk patients considered together and it was not detected in the group of patients with classical MS. It 
was also found in patients with “masked” NMO. The staining pattern distribution was compatible with 
the localization of the autoantigen in the blood brain barrier [3]. A year later the same group discovered 
that NMO-IgG reacts against the water channel aquaporin-4 (AQP4). The staining with NMO-IgG was 
intense in pial and microvascular elements in the brain and interestingly it was present in the distal urine-
collecting tubules in the renal medulla and in gastric parietal cells. This staining distribution suggested 
that the AQP4 was a candidate antigen. This result was supported by the lack of staining of CNS tissue in 
AQP4-null mice and the selective staining of AQP4-transfected cells membranes. So, for the first time, an 
autoantibody associated with NMO was described and the responsible autoantigen was identified and 
implicated in the pathogenesis of this autoimmune disease [4]. 
With this discovery a new step was taken: the NMO diagnostic criteria were revised and NMO-IgG 
positive diseases broadened NMO to a spectrum of diseases [5,6]. 
Meanwhile some evidence demonstrated the close relationship between NMO and other autoimmune 
diseases and consequently a renewed interest in this area appeared [7]. 
There was an increase in the investigation in all these areas and our aim with this paper is to review the 
new data about this subject and approach the criteria used to diagnose the group of diseases that constitute 
the NMO spectrum diseases (NMOSD), the connections between NMO, NMOSD and autoimmune 
diseases and compile the information about the treatments available for this very incapacitating disease. 
Pubmed was searched for articles in English from 01/01/2004 until 31/09/2013. Search terms included 
“Neuromyelitis optica spectrum diseases”, “Neuromyelitis optica AND autoimmune diseases”, 
“Neuromyelitis optica AND myasthenia gravis”, Neuromyelitis optica AND sjögren syndrome”, 
“Neuromyelitis optica AND systemic lupus erythematosus”, “Neuromyelitis optica AND treatment” and 
“Neuromyeilits optica AND sarcoidosis”. Titles and abstracts were reviewed and prioritized by relevance. 
Some articles were obtained through reference articles’ bibliography.  
NMO and NMO spectrum disorders diagnosis 
According to the latest guidelines (2010) from the European Federation of Neurological Societies (EFNS) 
the diagnostic criteria of NMO are: 
Two absolute criteria: 
(i) Optic Neuritis (ON), and 
 (ii) Myelitis. 
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At least two of three supportive criteria: 
(i) Presence of contiguous spinal cord magnetic resonance image (MRI) lesion extending over 
three or more vertebral segments, 
(ii) MRI not satisfying the revised (2010) McDonald diagnostic criteria for MS [8], and 
(iii) NMO-IgG in serum [1]. 
Since the demonstration of NMO-IgG, a spectrum of diseases with some similarities with NMO but not 
fulfilling the criteria for the diagnosis for this disease was created. The fact that the patients with NMO 
spectrum diseases were most of the time positive for NMO-IgG raised the need to find a new 
classification and the concept of NMOSD was created [9]. 
So the NMOSD comprises pathologies resembling NMO and/or frequently associated with NMO-IgG 
positivity: 
1. Neuromyelitis optica; 
2. Limited forms of neuromyelitis optica:  
- Idiopathic single or recurrent events of longitudinally extensive myelitis (LETM; ≥ 3 
vertebral segment spinal cord lesion seen on MRI); 
- Optic neuritis : recurrent or simultaneous bilateral; 
3. Asian optic-spinal multiple sclerosis; 
4. Optic neuritis or longitudinally extensive myelitis associated with systemic autoimmune disease; 
5. Optic neuritis or myelitis associated with brain lesions typical of Neuromyelitis Optica 
(hypothalamic, corpus callosal, periventricular or brainstem) [9,1,10,11]. 
Association with autoimmune diseases 
There is some evidence that NMO-IgG seropositivity might be associated with organ-specific 
autoimmune diseases like myasthenia gravis (MG), hypothyroidism, pernicious anaemia, ulcerative 
colitis, primary sclerosing cholangitis, and idiopathic thrombocytopenic purpura.  On the other 
handSjögren syndrome (SS), sarcoidosis, antiphospholipid syndrome (APLS) or systemic lupus 
erythematosus (SLE) are examples of non-organ-specific autoimmune diseases associated with NMO 
[12,13]. The mechanism by which this association exists is unknown and it is unknown if these diseases 
are the primary cause of NMOSD or a concomitant autoimmune disease [14].  
One study evaluated the sera of 183 patients (153 from the USA and 30 from France) and suggested that 
NMOSD occurring with other autoimmune diseases is a concurrent pathology and not a vasculopathy or 
other complications of the connective tissue diseases (CTD) [7].  
Smaller series and some case reports are present in the literature and we will try to review most of them. 
Myasthenia gravis 
One article from 2009 described a high frequency of MG (2%) and a higher presence of anti-acetilcholine 
receptors (anti-AchR) antibodies (11%) in NMO patients while in MS and healthy controls the antibody 
was not detected [15]. 
Another paper from 2009 analyzed 15 cases of MG and NMO and in all of them MG onset happened 
before NMO. 13 of the 15 cases had undergone thymectomy before NMOSD onset and this surgery has 
been associated with immune deregulation and triggering autoimmune diseases because of the inability to 
produce immunosuppressive T cells [16]. In 2011, a group of 26 patients with MG and NMOSD was 
described and the authors observed similar features [17].  In another multicenter study with 16 patients 
MG was developed before NMOSD in patients after thymectomy [18].  
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Usually NMOSD occurs after MG onset and after thymectomy. One case report, from 2008, was the first 
described case of a patient with NMOSD after MG onset without thymectomy performed at any stage of 
the follow-up. [19]   
Another study, from 2010, analyzed 10 patients with thymoma (9 with MG) and demonstrated that these 
tumors (with or without MG) express AQP-4. The authors suggested that this can be a mechanism that 
predisposes to NMOSD if there is a predisposition for autoimmunity and the generated antibodies against 
AQP-4 from thymoma are available to cross the blood-brain barrier (causing a paraneoplatsic NMOSD) 
[20].  
One study from 2013 analyzed autoantibodies and autoimmune diseases associated with MG. 2 patients 
with NMOSD after the onset of MG in the group of early onset MG were described. This study concluded 
that the autoimmunity associated with MG is focused and not generalized or random deserving a more 
selective immunossuppression [21]. Another group studied antibodies detected by cell based assays in 
MG patients and calculated that anti-AchR antibodies and NMO-IgG occur together 70 times more 
frequently than would be expected by chance in the British population [22]. 
Sjögren syndrome 
One study from 2008 described 25 patients with NMOSD and 13 in 24 patients had positive NMO-IgG 
and 4 patients of the 25 had criteria for the diagnosis of SS. Of 20 patients with labial salivary gland 
biopsy 16 were positive; however only 4 had elevated anti-SSA antibodies. The authors suggest a cross 
reaction with NMO-IgG and performing a labial salivary gland biopsy and anti-SSA measurement in 
patients with NMOSD and suspected SS [23].  
In 2009 one group suggested that SS myelopathy can be a manifestation of NMO. The authors described 
112 patients with SS and 8 of them had spinal cord lesions. In 5 patients NMO-IgG was measured: 4 were 
positive and the other had borderline levels of this auto-antibody. Three other patients had clinical and 
imagiological criteria for NMO diagnosis. The NMO-IgG was not detected in patients without CNS 
evolvement [24].  
Another group analyzed brain abnormalities in SS with recurrent CNS manifestations. 12 patients were 
evaluated and 10 had CNS manifestations demonstrated by CNS MRI before the onset of SS. NMO-IgG 
was positive in 6 of the 8 patients tested. After all the analyses 9 patients had NMOSD criteria. This study 
also showed a positive association between the NMO-IgG levels and the relapse frequency [25]. 
 In another article 17 patients with acute myelitis were studied and followed up for 12 years. They were 
diagnosed with SS (6), SLE (5), SS/SLE overlap (2), MS/SS overlap (2) and NMO only (2). Amongst the 
patients with SS, 4 had positive NMO-IgG and no patient with SLE alone was positive for this antibody. 
Eight patients of the 15 diagnosed with CTD had criteria for NMOSD and of these 3 had a diagnosis of 
CTD before myelitis. The 6 patients with NMO-IgG positivity experienced disease relapses and of the 
NMO-IgG negative patients only 3 had disease relapse [13].  
A case report from 2007 described a 10-year-old patient with NMO at presentation. NMO-IgG 
measurement was not available. He had anti-SSA and anti-SSB antibodies but SS was diagnosed with 
minor salivary gland biopsy because there were no other symptoms only 10 years later [26]. Another case 
report described a patient with myelitis, positive anti-SSA antibody and positive minor salivary gland 
biopsy without relevant brain MRI abnormalities at the onset of the disease. NMO-IgG was positive [27]. 
A recent case report described a patient with bilateral ON presentation with a history of sicca symptoms 
for 12 years without SS diagnosis at NMOSD onset. The authors suggest that with this case and the data 
available in the literature ON in patients with SS and NMO-IgG positivity are arguments to the 
coexistence of two concurrent autoimmune diseases instead of a consequence of vasculitic complications  
[28]. 
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One case report described a patient presenting first with SS and brain lesions afterwards. One year later 
NMO-IgG was measured and it was positive. After this the patient had several relapses however without 
ON or LETM [29]. Another case report described a patient with anti-SSA antibodies but without sicca 
symptoms. She presented ON later and NMO-IgG was negative. However, with brain MRI and evidence 
of myelitis, NMOSD criteria were fullfiled [30].  
Systemic Lupus Erythematosus 
In 2012 one group evaluated 626 hospitalized patients with SLE or SS and measured NMO-IgG in 6 
patients (3 with SLE and 3 with SS) with suspected NMOSD. One patient with SLE and one with SS 
were NMO-IgG positive while the other only had anti-SSA antibodies. As NMOSD doesn’t develop in 
most patients with anti-SSA antibodies the authors conclude that it is unlikely that this antibody is 
responsible for NMOSD manifestations. The authors conclude that NMO-IgG is present in some patients 
with SLE and SS and it can have a reflection in the patient’s outcome [31].  
Two case reports of NMOSD presentation with previous history of SLE were available. One of those 
patients had several relapses after NMOSD onset [32]. The other also had APLS and a recent episode of 
cervical myelitis [33]. 
Another case report described a woman with sicca symptoms for 20 years presenting with myelitis and 
brain lesions with MRI confirmation. The serology verified the diagnosis of SLE/NMOSD. The patient 
had multiple relapses in the following years [34]. 
A recent case report described a 51-year-old female patient with type 2 diabetes mellitus, hypertension 
and peripheral arterial disease. She presented with NMOSD with MRI confirmation and NMO-IgG 
positivity. SLE features with positive antibodies were described in the following years [35].   
Another paper reported the case of a 39-year-old woman without previous diseases. She presented with 
NMOSD with MRI findings suggestive of acute myelitis. The measured serological markers were 
positive for anti-nuclear antibodies (ANA), anti-double strand DNA antibodies (dsDNA) and 
anticardiolipin with low C3 and C4. NMO-IgG was not measured. During the follow-up she developed 
typical findings of SLE (malar rash and photosensitivity) [36]. 
Systemic sclerosis 
A first case report describing NMOSD associated with Systemic Sclerosis (SSc) was available.  A female 
patient presented with LETM (C6-T6) and brain lesions with MRI confirmation. CSF analysis and all the 
other tests were normal. She had a relapse with NMO-IgG positivity. Later the diagnosis of SSc was 
made [37].  
Sarcoidosis 
A single case from 2013 was available describing NMO with concomitant sarcoidosis. A 45- year-old 
patient presented with acute myelitis and 5 years later she had a relapse with positive NMO-IgG. Due to 
an abnormal thorax CT scan, a biopsy of the supraclavicular lymph node was performed which revealed 
noncaseating granulomatous lesions [38]. 
Because of all this evidence and clinical experience it is recommended that NMO-IgG should be 
measured in patients with CTD, atypical presentations of CTD neurological symptoms and signs or 
symptoms that are suggestive of NMOSD allowing a better diagnosis, treatment and prognosis [12].  
The following table (table 1) summarizes the case reports referred in the text above.
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Table 1 – NMOSD associated with other autoimmune diseases case reports 
Reference Sex/Origin/age Presentation/ 
age at onset 
NMO-IgG Brain-MRI Spinal-MRI CSF Age at NMOSD 
diagnosis /Relapses 
Other ABDs Time until final 
diagnosis/Final 
treatment 
MG  
Kay et al. 
2008 
F/Jap/44 y.o. MG/44 y.o. + + + N 49 y.o./ 3 - 5 years/AZA 
SS  
Gokcay et al. 
2007 
F/-/20 y.o NMO/ 10 y.o. N.P. N + N.P. 10 y.o /7 Anti-SSA and 
Anti-SSB + 
10 years/PRED 
+AZA + CYC 
Min et al. 
2010 
F/- /35 y.o. SS/35 y.o. + + N.P N.P. 38 y.o./3 Anti-SSA and 
Anti-SSB + 
3 years/N.A. 
Koga et al. 
2011 
F/Jap/31 y.o. SS?/25 y.o. - N + N 31 y.o/1 ANA and anti-
SSA 
6 years/PP+ PRED 
Kahlenberg et 
al. 2011 
F/AA/54 y.o NMO/54 y.o. + N + N 54 y.o. /0 ANA and anti 
-SSA + 
0 years/PP+ PRED 
Tan et al. 
2012 
F/Chi/56 y.o. NMO/56 y.o. + N N.P. N 56 y.o./0 ANA, RF, 
anti-SSA 
0 years/ MP+PP 
SLE  
Birnbaum et 
al. 2008 
F/AA/38 y.o. SLE/36 y.o. + + + N 38 y.o./3 ANA, anti- 
dsDNA + 
2 years/RTX 
Mottaghi et 
al. 2009 
F/-/34 y.o. NMO/34 y.o. Not tested - + N.P. 34 y.o./ ANA, anti-
dsDNA, anti-
cardiolipin + 
0 years/ PRED+CYC 
Polgár et al. 
2011 
F/ Cau/48 y.o. NMO/48 y.o. + + + N.P. 52 y.o./6 ANA, anti-
cardiolipin and 
anti SSA + 
4 years/ 
MPRED+CYC 
Arul Selvan 
et al. 2013 
F/-/51 y.o. NMO/51 y.o. + + + + (without 
OCBs)  
52 y.o./2 Anti- dsDNA, 
ANA + 
1 year/AZA 
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Mehta et al. 
2008 
F/AA/47 y.o. SLE/ “Long 
standing 
history” 
+ - 
 
+ N.P. 47 y.o./2 ANA, APLS 
antibody + 
0 years/ 
CST+PP+CYC 
Sarcoidosis  
Sawaya e tal.  
2013 
F/-/50 y.o NMO/45 y.o. + + + + (without 
OCBs) 
50 y.o./1 ANA, anti- 
dsDNA + 
5 years/ IVIG+RTX 
SSc  
Franciotta et 
al. 2013 
F/-/62  y.o. NMO/62 y.o. + + + + 63 y.o./2 ANA +  1 year/ MPRED 
AA - Afroamerican. ABDs – antibodies. ANA- anti-nuclear antibody. APLS – antiphospholipid  syndrome antibody. AZA – Azathioprine. Cau- Caucasian. Chi- Chinese. 
CSF – Cerebrospinal fluid. CST – corticosteroids.  CYC – Cyclophosphamide. F – Female. IVIG – intravenous immunoglobulin.  Jap- Japanese. MG- Myasthenia gravis. MP 
– Methylprednisolone. MRI - Magnetic ressonance imaging. N.A. – not available. N.P – not performed. NMO – Neuromyelitis Optica. NMO-IgG – anti-aquaporin 4 
autoantibody. NMOSD – Neuromyelitis Optica Spectrum Disorder. OCBs – oligoclonal bands. PP – Plasmapheresis. PRED - Prednisone. RF –Rheumatoid factor. RTX – 
Rituximab. SLE- Systemic lupus erythematosus. SS - Sjögren syndrome. SSc – Systemic Sclerosis. Y.o - years old. + (positive). - (negative).
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Biomarkers  
NMO-IgG is an autoantibody against aquaporin-4 (AQP4), the major water channel in the central nervous 
system. AQP4 is localized in the astrocytic foot processes and is the major agent responsible for the water 
balance in brain but also for glutamate and potassium regulation in the blood-brain-barrier, synapses and 
paranodes adjacent to the nodes of Ranvier [39,1,40]. The AQP4 is also expressed in the kidneys but 
renal function seems to be normal in NMOSD possibly because of its small role in water balance in the 
nephron [9].  
Binding of NMO-IgG to AQP4 has several consequences, contributing to its downregulation which 
causes significant damage in the astrocytic foot processes and consequently in the affected neurons. It is 
accepted that this pathologic mechanism has inflammatory effects through different pathways including 
complement and cell-based damage which cause inflammation, demyelination and oedema of the CNS 
[40,41].  It is suggested that NMO-IgG increases the blood-brain barrier permeability leading to higher 
penetration of autoantibodies, complement-dependent granulocytes and antigen-specific T-cells [42].  
The antibodies detection in the patients’ serum can be achieved by indirect immunofluorescence or 
immunohistochemistry. The sensitivities and specificities are diverse but the used methods generally have 
an excellent specificity and a good sensitivity. Comparing the most commonly used assays 
(immunofluorescence, cell-based and fluorescence-based immunoprecipitation assays) it seems that the 
cell-based assay has the highest sensitivity (91%) and specificity (100%) comparable to the others 
[43,44]. Another study also demonstrated that the cell based assay is the most sensitive method and it is 
simple and easy to use in routine laboratories [45].  With this level of sensitivity is recommended that 2 
different assays should be used and one of them should be indirect immunofluorescence [46].  
In 2012 one group used 673 serum samples to study the specificity of the NMO-IgG in the context of 
autoimmune diseases and non-immune mediated diseases. This antibody was detected in none of the 585 
samples without CNS manifestations. None of the SS or SLE patients had CNS involvement and NMO-
IgG was negative. This study concluded that this test is very specific and if it is positive in other 
autoimmune diseases with CNS lesion, concurrent NMOSD is probable [47]. 
Routine CSF analysis can be useful in patients with NMOSD onset when clinical and imagiological 
distinction from Multiple Sclerosis is difficult. In contrast with MS, in NMO pleocytosis consisting of 
monocytes and lymphocytes is present in 14-79% of patients. The frequency of oligoclonal bands ranges 
from 0-37% in NMO unlike in MS where it is a common finding. Increased protein levels are present in 
46-75% of the patients. Neurofilaments heavy chain levels are significantly higher than in patients with 
MS [48,13,1].  
NMO-IgG detection in CSF didn’t improve the sensitivity or specificity of the current diagnosis criteria 
[49]. In another study a Chinese group demonstrated increased sensitivity of NMO-IgG detection in CSF 
when compared with serum [50]. However, NMO-IgG analysis in CSF is recommended in cases where 
there are AQP4 seronegative NMO/ NMOSD with elevated clinical or image suspicion [1].  
Other diagnostic exams are being tested. The complement activating antibodies against myelin 
oligodendrocyte glycoprotein (MOG), a biomarker associated with acute disseminated encephalomyelitis, 
and their detection in serum can be a useful tool in seronegative NMO-IgG patients that have criteria for 
NMO or NMOSD, suggesting an alternative lesion mechanism [51]. Another study demonstrated that 
during initial NMOSD attacks interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) in CSF are 
elevated suggesting that their detection can also allow an early diagnosis [52]. Another study compared 
GFAP in patients with ON associated with MS and with NMO. The findings were statistically significant 
and demonstrated that GFAP levels in patients with ON related to NMO are higher than those in MS 
suggesting that it can be a good biomarker in atypical presentations [53]. One single study suggested that 
high-mobility group box 1 protein (HMGB1) in serum can be used as an early diagnostic tool in NMO, 
making its distinction from MS possible [54].  
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Recently, one group suggested that in NMOSD NMO-IgG seronegative patients anti-aquaporin1 antibody 
can be one alternative biomarker (another aquaporin present in the CNS) that was present in a subgroup 
of patient with demyelinating disease similar to NMOSD [55]. 
Brain MRI findings 
After the discovery of NMO-IgG the brain lesions in NMOSD began being commonly described.  
Characteristic abnormalities are: 
-Transverse myelitis, clinically complete or incomplete, but associated with imagiological evidence of 
spinal cord lesion extending over three or more spinal segments on T2-weighted MRI and hypointensity 
on T1-weighted images when obtained during acute episode of myelitis. 
-Non-specific brain T2 signal abnormalities not satisfying Macdonald criteria 
-Lesions in the dorsal medulla, either in contiguity or not with a spinal cord lesion 
-Hypothalamic and/or brainstem lesions 
-“Linear” periventricular/ corpus callosum signal abnormalities, not ovoid, and not extending into the 
parenchyma of the cerebral hemispheres in Dawson finger configuration [56]. 
New MRI techniques are being used in NMOSD. Diffusion tensor image showed that multiple white 
matter tracts and other normal appearing white matter are involved. Magnetic ressonance spectroscopy 
analysis was normal in normal appearing grey and white matter in NMO patients for the main metabolic 
parameters. Voxel based morphometry allows the study of structural changes of the brain and 
demonstrated that the decrease of global and focal white matter in NMO appears to be correlated with 
cognitive impairment [5]. 
In contrast with what was previously defended it was demonstrated that brain lesions can also be the first 
manifestation of NMOSD in two studies of 15 and 27 NMO-IgG seropositive patients [57,58].      
In vasculitic diseases related with other autoimmune diseases the MRI abnormalities are diverse. One 
review of the imaging of cerebral vasculitits suggested a new organization of the signs of this type of 
brain disease in direct and indirect. The direct sign is applied mainly in large vessels and in this case a 
vessel wall thickening is detected with contrast enhancement. The indirect signs can be suggested by 
cerebral perfusion deficits, ischaemic brain lesions, cerebral haemorrhage and vascular stenosis unlikely 
to be atherosclerotic [59]. 
Another study analyzed, among other things, the differences in MRI imaging in the diagnosis of several 
autoimmune diseases. In SS myelopathy the MRI findings may be similar to those of NMO with LETM 
and gadolinium-enhancing. Concerning SLE, the MRI imaging pattern seems to be very similar to MS 
and acute SLE lesions often enhance with gadolinium. One common finding in these patients is cortical 
atrophy (which can be also found in MS and in other autoimmune diseases with SNC manifestations). 
The spinal cord imaging can show LETM (sometimes the entire length of spinal cord) differently from 
MS [60]. 
It is suggested that MRI evaluation in patients with autoimmune diseases, SNC lesions and positive 
NMO-IgG might be useful, allowing an early diagnosis and better prognosis, with a closer follow-up. 
Treatment 
There are no published randomized controlled trials for relapse prevention in NMOSD. However, there 
are recommended drugs based on small prospective or retrospective series of off-label use. For acute 
treatment methylprednisolone is the first line treatment [61]. When the patient doesn’t improve, plasma 
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exchange can be a good alternative [62,63]. Cyclophosphamide also seems to be a good alternative in 
refractory cases [64]. 
For relapse prevention several drugs can be used. Azathioprine (first line drug), mycophenolate mofetil 
and methotrexate are immunosuppressant drugs that seem to be safe and significantly reduce annual 
relapses rate (ARR) and improve or stabilize Expanded Disability Status Scale (EDSS) [61,65,66]. Other 
alternatives are available: rituximab, for instance, is a promising drug in refractory cases reducing ARR 
and EDSS [67-69]. A new alternative is eculizumab (monoclonal IgG) that neutralizes complement 
protein C5 and seems to reduce ARR and stabilize or improve EDSS [70]. 
According with Wingerchuk and Weinshenker [14] the therapeutic regimen in NMO with concomitant 
rheumatologic diseases can be based in cyclophosphamide and methotrexate because these agents showed 
benefits in both conditions. However, azathioprine should be the drug of choice because of its safety 
profile and tolerance in long-term therapy. The authors recommend avoiding monoclonal antibodies or 
fusion protein therapies that can interfere with tumor necrosis factor-alpha function (infliximab, 
adalimumab, etanercept). These agents are commonly used in rheumatic disorders but are associated with 
demyelinating events and their effect in NMO is not known [14]. Another paper reporting 2 patients with 
NMO and SLE overlap described a good response to cyclophosphamide and azathioprine [34]. Another 
review described the efficacy of Rituximab in NMO, MG and SLE and in the latter it can be used alone or 
in combination with corticosteroids or cyclophosphamide [71]. Methylprednisone is also commonly used 
in autoimmune diseases and NMO mainly in acute manifestations [16,60]. Plasma exchange is also an 
alternative in these patients, as seems to be intravenous immunoglobulins [72,73].  
Conclusions 
NMOSD are very incapacitating diseases with serious consequences in the quality of life and causing 
serious loss of autonomy in these patients. 
With the present review we tried to summarize the developments in diagnosis and treatment of NMOSD 
with special focus in the relationship with other autoimmune diseases and in the recent investigation made 
in this field. 
There was an increase in the investigation in this area mostly motivated by the discovery of NMO-IgG 
antibody which allowed the identification of several diseases that previously were not considered as 
belonging to the field of NMO.   
This antibody allowed an early recognition and diagnosis of NMOSD also allowing an accurate 
distinction between NMOSD, MS or other manifestations of autoimmune diseases (vasculitis e.g.) when 
the criteria previously mentioned are not clearly fulfilled.  
There are some new biomarkers being discovered and associated with NMOSD and they can be useful for 
a more accurate diagnosis and early treatment in the future. 
The neuroimaging is also in progress and new diagnostic tools are becoming available turning possible 
the identification of brain lesions where before it was not possible. 
Further investigation is needed and new trials with recent drugs must be performed. The small number of 
patients with NMOSD restricts the possibility of large scale trials to demonstrate the efficacy of the old 
drugs and to show the advantage of new emerging drugs. We tried to summarize the most useful 
treatments that can be useful in both diseases NMO and other autoimmune diseases. The number of 
studies considering overlapping diseases is reduced and more investigation is needed to evaluate the 
efficacy and safety of different treatments.  
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The number of cases of NMOSD associated with other autoimmune diseases available in the literature is 
limited and further investigation is needed to increase the knowledge and the validity of the conclusions 
taken from the developed research. 
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accepting Case Reports until further notice. Authors wishing to submit a Case
Report should either wait until the moratorium ends or extend their Case Report
and submit it as a Short Communication
Letters to editor: up to 600 words
MANUSCRIPT SUBMISSION
Instructions for Authors
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Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before;
that it is not under consideration for publication anywhere else; that its publication has been
approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly
– at the institute where the work has been carried out. The publisher will not be held legally
responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published
elsewhere are required to obtain permission from the copyright owner(s) for both the print and
online format and to include evidence that such permission has been granted when
submitting their papers. Any material received without such evidence will be assumed to
originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces
the editorial processing and reviewing times and shortens overall publication times. Please
follow the hyperlink “Submit online” on the right and upload all of your manuscript files
following the instructions given on the screen.
TITLE PAGE
Title Page
The title page should include:
The name(s) of the author(s)
A concise and informative title
The affiliation(s) and address(es) of the author(s)
The e-mail address, telephone and fax numbers of the corresponding author
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any
undefined abbreviations or unspecified references.
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
TEXT
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 10-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word
versions).
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LaTeX macro package (zip, 182 kB)
Manuscripts with mathematical content can also be submitted in LaTeX.
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a
reference included in the reference list. They should not consist solely of a reference citation,
and they should never include the bibliographic details of a reference. They should also not
contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by
superscript lower-case letters (or asterisks for significance values and other statistical data).
Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section
before the reference list. The names of funding organizations should be written in full.
SCIENTIFIC STYLE
Generic names of drugs and pesticides are preferred; if trade names are used, the generic
name should be given at first mention.
REFERENCES
Citation
Reference citations in the text should be identified by numbers in square brackets. Some
examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been
published or accepted for publication. Personal communications and unpublished works
should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a
reference list.
The entries in the list should be numbered consecutively.
Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L
(2009) Effect of high intensity intermittent training on heart rate variability in
prepubescent children. Eur J Appl Physiol 105:731-738. doi: 10.1007/s00421-008-
0955-8
Ideally, the names of all authors should be provided, but the usage of “et al” in long
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EndNote style (zip, 2 kB)
author lists will also be accepted:
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J
Med 965:325–329
Article by DOI
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine
production. J Mol Med. doi:10.1007/s001090000086
Book
South J, Blass B (2001) The future of modern genomics. Blackwell, London
Book chapter
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern
genomics, 3rd edn. Wiley, New York, pp 230-257
Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb.
http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
Dissertation
Trent JW (1975) Experimental acute renal failure. Dissertation, University of
California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title
Word Abbreviations, see
ISSN.org LTWA
For authors using EndNote, Springer provides an output style that supports the formatting of
in-text citations and reference list.
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is
included in Springer’s LaTeX macro package.
TABLES
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of
the table.
Identify any previously published material by giving the original source in the form
of a reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters (or
asterisks for significance values and other statistical data) and included beneath
the table body.
ARTWORK AND ILLUSTRATIONS GUIDELINES
For the best quality final product, it is highly recommended that you submit all of your artwork –
photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the
highest standards with the greatest accuracy to detail. The published work will directly reflect
the quality of the artwork provided.
Electronic Figure Submission
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Supply all figures electronically.
Indicate what graphics program was used to create the artwork.
For vector graphics, the preferred format is EPS; for halftones, please use TIFF
format. MS Office files are also acceptable.
Vector graphics containing fonts must have the fonts embedded in the files.
Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
Definition: Black and white graphic with no shading.
Do not use faint lines and/or lettering and check that all lines and lettering within
the figures are legible at final size.
All lines should be at least 0.1 mm (0.3 pt) wide.
Scanned line drawings and line drawings in bitmap format should have a
minimum resolution of 1200 dpi.
Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
Definition: Photographs, drawings, or paintings with fine shading, etc.
If any magnification is used in the photographs, indicate this by using scale bars
within the figures themselves.
Halftones should have a minimum resolution of 300 dpi.
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Combination Art
Definition: a combination of halftone and line art, e.g., halftones containing line
drawing, extensive lettering, color diagrams, etc.
Combination artwork should have a minimum resolution of 600 dpi.
Color Art
Color art is free of charge for online publication.
If black and white will be shown in the print version, make sure that the main
information will still be visible. Many colors are not distinguishable from one
another when converted to black and white. A simple way to check this is to make a
xerographic copy to see if the necessary distinctions between the different colors
are still apparent.
If the figures will be printed in black and white, do not refer to color in the captions.
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Color illustrations should be submitted as RGB (8 bits per channel).
Figure Lettering
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
Keep lettering consistently sized throughout your final-sized artwork, usually about
2–3 mm (8–12 pt).
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt
type on an axis and 20-pt type for the axis label.
Avoid effects such as shading, outline letters, etc.
Do not include titles or captions within your illustrations.
Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.).
If an appendix appears in your article and it contains one or more figures, continue
the consecutive numbering of the main text. Do not number the appendix figures,
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material)
should, however, be numbered separately.
Figure Captions
Each figure should have a concise caption describing accurately what the figure
depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number,
also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be
placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes,
circles, etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a
reference citation at the end of the figure caption.
Figure Placement and Size
When preparing your figures, size figures to fit in the column width.
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide
and not higher than 234 mm.
For books and book-sized journals, the figures should be 80 mm or 122 mm wide
and not higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain
permission from the copyright owner(s) for both the print and online format. Please be aware
that some publishers do not grant electronic rights for free and that Springer will not be able to
refund any costs that may have occurred to receive these permissions. In such cases,
material from other sources should be used.
Accessibility
In order to give people of all abilities and disabilities access to the content of your figures,
please make sure that
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All figures have descriptive captions (blind users could then use a text-to-speech
software or a text-to-Braille hardware)
Patterns are used instead of or in addition to colors for conveying information
(color-blind users would then be able to distinguish the visual elements)
Any figure lettering has a contrast ratio of at least 4.5:1
ELECTRONIC SUPPLEMENTARY MATERIAL
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other
supplementary files to be published online along with an article or a book chapter. This feature can
add dimension to the author's article, as certain information cannot be printed or is more convenient in
electronic form.
Submission
Supply all supplementary material in standard file formats.
Please include in each file the following information: article title, journal name, author
names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require
very long download times and that some users may experience other problems during
downloading.
Audio, Video, and Animations
Always use MPEG-1 (.mpg) format.
Text and Presentations
Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
A collection of figures may also be combined in a PDF file.
Spreadsheets
Spreadsheets should be converted to PDF if no interaction with the data is intended.
If the readers should be encouraged to make their own calculations, spreadsheets should
be submitted as .xls files (MS Excel).
Specialized Formats
Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and
.tex can also be supplied.
Collecting Multiple Files
It is possible to collect multiple files in a .zip or .gz file.
Numbering
If supplying any supplementary material, the text must make specific mention of the
material as a citation, similar to that of figures and tables.
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation
(Online Resource 3)", “... additional data are given in Online Resource 4”.
Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.
Captions
For each supplementary material, please supply a concise caption describing the content
of the file.
Processing of supplementary files
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Electronic supplementary material will be published as received from the author without
any conversion, editing, or reformatting.
Accessibility
In order to give people of all abilities and disabilities access to the content of your supplementary files,
please make sure that
The manuscript contains a descriptive caption for each supplementary material
Video files do not contain anything that flashes more than three times per second (so that
users prone to seizures caused by such effects are not put at risk)
CONFLICT OF INTEREST
Authors must indicate whether or not they have any conflicts of interest; this may include:
Consultancies, stock ownership, equity interest, patent/licensing arrangements,
etc. related to the content of their manuscript
Whether the authors have directly received any research funding and the role of
their funding source
Whether the authors have any conflicts of interest in relation to the research topic
Etc.
This note should be included on the separate title page submitted alongside the blinded
manuscript file, as detailed in the ‘Editorial Procedure’ section of these instructions for
authors. If no conflict exists, authors should state: The authors declare that they have no
conflict of interest.
All authors must include a signed ICMJE Conflict of Interest form before their manuscript can
be accepted by Rheumatology International; this form can be submitted at initial submission
or upon hearing the acceptance decision from the Editor-in-Chief. To download a copy of this
form please select the link on the right hand side of this page.
DOES SPRINGER PROVIDE ENGLISH LANGUAGE SUPPORT?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and
formal style. This may not be sufficient if English is not your native language and substantial editing
would be required. In that case, you may want to have your manuscript edited by a native speaker prior
to submission. A clear and concise language will help editors and reviewers concentrate on the
scientific content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in all areas Springer
publishes in.
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
For Authors from China
文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐的编
辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的
内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系
Springer推荐的编辑服务公司，协商编辑事宜。
理文编辑
For Authors from Japan
ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社
をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループ
ジャパン株式会社の下記サイトをご覧ください。
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エダンズ グループ ジャパン
For Authors from Korea
영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서
비스 내용, 가격 및
신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니
다.
Edanz Editing Global
AFTER ACCEPTANCE
Upon acceptance of your article you will receive a link to the special Author Query Application
at Springer’s web page where you can sign the Copyright Transfer Statement online and
indicate whether you wish to order OpenChoice and offprints.
Once the Author Query Application has been completed, your article will be processed and
you will receive the proofs.
Open Choice
In addition to the normal publication process (whereby an article is submitted to the journal
and access to that article is granted to customers who have purchased a subscription),
Springer now provides an alternative publishing option: Springer Open Choice. A Springer
Open Choice article receives all the benefits of a regular subscription-based article, but in
addition is made available publicly through Springer’s online platform SpringerLink.
Springer Open Choice
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher
exclusive publication and dissemination rights). This will ensure the widest possible
protection and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the
author. In opting for open access, the author(s) agree to publish the article under the Creative
Commons Attribution License.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Publication of color illustrations is free of charge.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the
completeness and accuracy of the text, tables and figures. Substantial changes in content,
e.g., new results, corrected values, title and authorship, are not allowed without the approval
of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which
will be hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first
publication citable with the DOI. After release of the printed version, the paper can also be
cited by issue and page numbers.
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